DOSE REDUCTION OF A CANNABINOID CB1 RECEPTOR ANTAGONIST IN THE TREATMENT OF OVERWEIGHT OR OBESITY
O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce the unfavourable psychiatric side e...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SZILVASSY, ZOLTAN FLEMING, ALEXANDER G BROWNSTEIN, MIKE TORY, KALMAN ROTH, JESSE EGRI, JANOS LITERATI NAGY, PETER BERNATH, SANDOR KOLONICS, ATTILA VIGH, LASZLO |
| description | O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce the unfavourable psychiatric side effect of the latter.
L'amidoxime O-(3-pipéridino-2-hydroxy-1-propyl)-nicotinique ou sur un sel d'addition avec les acides pharmaceutiquement acceptables de celle-ci est administré à des patients souffrant de surpoids ou d'obésité et traité par un antagoniste des récepteurs cannabinoïdes CB1 tels que le rimonabant pour réduire l'effet secondaire psychiatrique défavorable de ce dernier. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2009074835A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2009074835A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2009074835A13</originalsourceid><addsrcrecordid>eNqNi8EKglAQRd20iOofBloHmkW1HJ-jzqKZeE5JK5F4raIE-38y6ANaXQ7n3GnU5VoTeMrPzlgFtAAEhyKYsSjn4LJk1I5Oph5QDEsVrg1YwCoC84R2JLHvUy_kG-KyGsmDZlSzXefR5N49hrD47SxaFmSuWoX-1Yah727hGd5to-s4PsS7zT7dYpL-V30ASRA0Xw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>DOSE REDUCTION OF A CANNABINOID CB1 RECEPTOR ANTAGONIST IN THE TREATMENT OF OVERWEIGHT OR OBESITY</title><source>esp@cenet</source><creator>SZILVASSY, ZOLTAN ; FLEMING, ALEXANDER G ; BROWNSTEIN, MIKE ; TORY, KALMAN ; ROTH, JESSE ; EGRI, JANOS ; LITERATI NAGY, PETER ; BERNATH, SANDOR ; KOLONICS, ATTILA ; VIGH, LASZLO</creator><creatorcontrib>SZILVASSY, ZOLTAN ; FLEMING, ALEXANDER G ; BROWNSTEIN, MIKE ; TORY, KALMAN ; ROTH, JESSE ; EGRI, JANOS ; LITERATI NAGY, PETER ; BERNATH, SANDOR ; KOLONICS, ATTILA ; VIGH, LASZLO</creatorcontrib><description>O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce the unfavourable psychiatric side effect of the latter.
L'amidoxime O-(3-pipéridino-2-hydroxy-1-propyl)-nicotinique ou sur un sel d'addition avec les acides pharmaceutiquement acceptables de celle-ci est administré à des patients souffrant de surpoids ou d'obésité et traité par un antagoniste des récepteurs cannabinoïdes CB1 tels que le rimonabant pour réduire l'effet secondaire psychiatrique défavorable de ce dernier.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090618&DB=EPODOC&CC=WO&NR=2009074835A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090618&DB=EPODOC&CC=WO&NR=2009074835A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SZILVASSY, ZOLTAN</creatorcontrib><creatorcontrib>FLEMING, ALEXANDER G</creatorcontrib><creatorcontrib>BROWNSTEIN, MIKE</creatorcontrib><creatorcontrib>TORY, KALMAN</creatorcontrib><creatorcontrib>ROTH, JESSE</creatorcontrib><creatorcontrib>EGRI, JANOS</creatorcontrib><creatorcontrib>LITERATI NAGY, PETER</creatorcontrib><creatorcontrib>BERNATH, SANDOR</creatorcontrib><creatorcontrib>KOLONICS, ATTILA</creatorcontrib><creatorcontrib>VIGH, LASZLO</creatorcontrib><title>DOSE REDUCTION OF A CANNABINOID CB1 RECEPTOR ANTAGONIST IN THE TREATMENT OF OVERWEIGHT OR OBESITY</title><description>O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce the unfavourable psychiatric side effect of the latter.
L'amidoxime O-(3-pipéridino-2-hydroxy-1-propyl)-nicotinique ou sur un sel d'addition avec les acides pharmaceutiquement acceptables de celle-ci est administré à des patients souffrant de surpoids ou d'obésité et traité par un antagoniste des récepteurs cannabinoïdes CB1 tels que le rimonabant pour réduire l'effet secondaire psychiatrique défavorable de ce dernier.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi8EKglAQRd20iOofBloHmkW1HJ-jzqKZeE5JK5F4raIE-38y6ANaXQ7n3GnU5VoTeMrPzlgFtAAEhyKYsSjn4LJk1I5Oph5QDEsVrg1YwCoC84R2JLHvUy_kG-KyGsmDZlSzXefR5N49hrD47SxaFmSuWoX-1Yah727hGd5to-s4PsS7zT7dYpL-V30ASRA0Xw</recordid><startdate>20090618</startdate><enddate>20090618</enddate><creator>SZILVASSY, ZOLTAN</creator><creator>FLEMING, ALEXANDER G</creator><creator>BROWNSTEIN, MIKE</creator><creator>TORY, KALMAN</creator><creator>ROTH, JESSE</creator><creator>EGRI, JANOS</creator><creator>LITERATI NAGY, PETER</creator><creator>BERNATH, SANDOR</creator><creator>KOLONICS, ATTILA</creator><creator>VIGH, LASZLO</creator><scope>EVB</scope></search><sort><creationdate>20090618</creationdate><title>DOSE REDUCTION OF A CANNABINOID CB1 RECEPTOR ANTAGONIST IN THE TREATMENT OF OVERWEIGHT OR OBESITY</title><author>SZILVASSY, ZOLTAN ; FLEMING, ALEXANDER G ; BROWNSTEIN, MIKE ; TORY, KALMAN ; ROTH, JESSE ; EGRI, JANOS ; LITERATI NAGY, PETER ; BERNATH, SANDOR ; KOLONICS, ATTILA ; VIGH, LASZLO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2009074835A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2009</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SZILVASSY, ZOLTAN</creatorcontrib><creatorcontrib>FLEMING, ALEXANDER G</creatorcontrib><creatorcontrib>BROWNSTEIN, MIKE</creatorcontrib><creatorcontrib>TORY, KALMAN</creatorcontrib><creatorcontrib>ROTH, JESSE</creatorcontrib><creatorcontrib>EGRI, JANOS</creatorcontrib><creatorcontrib>LITERATI NAGY, PETER</creatorcontrib><creatorcontrib>BERNATH, SANDOR</creatorcontrib><creatorcontrib>KOLONICS, ATTILA</creatorcontrib><creatorcontrib>VIGH, LASZLO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SZILVASSY, ZOLTAN</au><au>FLEMING, ALEXANDER G</au><au>BROWNSTEIN, MIKE</au><au>TORY, KALMAN</au><au>ROTH, JESSE</au><au>EGRI, JANOS</au><au>LITERATI NAGY, PETER</au><au>BERNATH, SANDOR</au><au>KOLONICS, ATTILA</au><au>VIGH, LASZLO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>DOSE REDUCTION OF A CANNABINOID CB1 RECEPTOR ANTAGONIST IN THE TREATMENT OF OVERWEIGHT OR OBESITY</title><date>2009-06-18</date><risdate>2009</risdate><abstract>O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce the unfavourable psychiatric side effect of the latter.
L'amidoxime O-(3-pipéridino-2-hydroxy-1-propyl)-nicotinique ou sur un sel d'addition avec les acides pharmaceutiquement acceptables de celle-ci est administré à des patients souffrant de surpoids ou d'obésité et traité par un antagoniste des récepteurs cannabinoïdes CB1 tels que le rimonabant pour réduire l'effet secondaire psychiatrique défavorable de ce dernier.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2009074835A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | DOSE REDUCTION OF A CANNABINOID CB1 RECEPTOR ANTAGONIST IN THE TREATMENT OF OVERWEIGHT OR OBESITY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A08%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SZILVASSY,%20ZOLTAN&rft.date=2009-06-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2009074835A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |